“…Residue Phe85 (VfTA)/Phe88 (CvTA)/Phe86 (PjTA), located in the small binding pocket, is frequently targeted and mutated to smaller residues like alanine, valine or leucine to relieve the steric hindrance limiting acceptance of bulky substituents (Midelfort et al, 2013;Sirin et al, 2014;Nobili et al, 2015;Genz et al, 2016;Voss et al, 2018;Land et al, 2020;Meng et al, 2021;Novick et al, 2021;Xiang et al, 2021;Sheludko et al, 2022). Another key residue in the small binding pocket is Val153 (VfTA)/Val154 (OaTA) and two smaller residues (alanine and serine) were tested (Midelfort et al, 2013;Sirin et al, 2014;Nobili et al, 2015;Dourado et al, 2016;Genz et al, 2016;Kim et al, 2019;Novick et al, 2021;Xiang et al, 2021). A key residue from the large binding pocket often responsible for steric hindrance with substrate is Trp57 (VfTA)/Trp60 (CvTA)/Trp58 (OaTA/PjTA), and mutations to smaller residues such as glycine, alanine, leucine, phenylalanine, and cysteine have been successful in reducing steric interference (Cho et al, 2008;Cassimjee et al, 2012;Midelfort et al, 2013;Sirin et al, 2014;Han et al, 2015cHan et al, , 2017Genz et al, 2015Genz et al, , 2016Dourado et al, 2016;Kim et al, 2019;Meng et al, 2021;Novick et al, 2021;Xiang et al, 2021).…”